Indaptus Therapeutics, Inc.
INDPNasdaq
$2.53
0.0%Jul 17 close · end-of-day
Price
1Y↓ -78.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$27.7M
Enterprise Value
$26.2M
P/E
—
P/S
—
P/B
22.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$18.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-1511.2%
ROIC
—
Debt / Equity
—
Net Cash
$1.5M
Return 1Y
-77.6%
Company profile
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
- CEO
- Jeffrey A. Meckler
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 6
- Headquarters
- New York
- Website
- indaptusrx.com
Management & directors
- Linscott Walt AddisonChief Operating Officer
- Meckler Jeffrey ACo-Chief Executive Officer
- Newman Michael JamesCSO and Director
- Sassi NirChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
INDP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.23↓ -97.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.6M | -$7.7M | -$14.9M | -$16.4M | -$15.4M | -$19.8M |
| Net income | -$3.6M | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| Diluted EPS | — | — | -$1.73 | -$1.83 | -$44.96 | -$21.58 |
| Operating cash flow | -$3.3M | -$11.3M | -$13.1M | -$13.4M | -$12.3M | -$14.8M |
| Free cash flow | — | -$11.3M | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.1M | -$3.1M | -$4.2M | -$4.6M | -$4.5M | -$2.6M | -$8.2M | -$2.2M |
| Net income | -$4.0M | -$3.1M | -$4.1M | -$4.5M | -$5.2M | -$3.0M | -$8.1M | -$2.5M |
| Diluted EPS | -$13.16 | -$9.04 | -$22.31 | -$9.11 | -$9.09 | -$2.98 | -$0.40 | -$0.23 |
| Operating cash flow | -$2.5M | -$2.5M | -$3.4M | -$5.0M | -$4.0M | -$2.6M | -$3.2M | -$7.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Dec 24, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-20 | Ben-Tzvi Avraham | Award | 25,000 | $0.00 | $0.00 | filing |
| 2025-12-22 | Meckler Jeffrey A· Co-Chief Executive Officer | Award | 216,617 | $2.03 | $439,732.51 | filing |
| 2025-12-22 | Linscott Walt Addison· Chief Operating Officer | Award | 54,421 | $2.03 | $110,474.63 | filing |
| 2025-12-22 | Newman Michael James· CSO and Director | Award | 52,204 | $2.03 | $105,974.12 | filing |
| 2025-12-22 | Sassi Nir· Chief Financial Officer | Award | 26,758 | $2.03 | $54,318.74 | filing |
| 2025-07-27 | Meckler Jeffrey A· Chief Executive Officer | Award | 6,068 | $8.30 | $50,378.96 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.